Where to start. Since may of 2018 when new leadership was put in place, over the past 1 .5yr the new Sr Leadership Team has driven out 5 C-level employees as well as the VP's/Functional Heads, not to mention several Director, Scientist and Associate level employees. And despite what should have been significant value inflection points (positive clinical data, alliances with major partners, initiation of clinical trails in significant disease areas), have driven the stock price well below book value.